A Pivotal Trial of Derazantinib in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2019
At a glance
- Drugs Derazantinib (Primary)
- Indications Cholangiocarcinoma
- Focus Registrational; Therapeutic Use
- Sponsors ArQule; Basilea Pharmaceutica
- 18 Jan 2019 Planned primary completion date changed from 1 Sep 2020 to 1 Jul 2020.
- 09 Jan 2019 Interim Results presented in the Basilea Pharmaceutica media release.
- 09 Jan 2019 Interim results (n=42) presented in a Basilea Pharmaceutica media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History